21 / 23
Pharma 2018
Page 49
E u r o p e a n C o n g r e s s o n
Pharma
A u g u s t 1 3 - 1 4 , 2 0 1 8
P a r i s , F r a n c e
American Journal of Pharmacology and Pharmacotherapeutics
ISSN: 2393-8862
C
atalytic Abs (catAbs) are multivalent im-munoglobulins (Igs) with a capacity to hy-drolyze the antigenic (Ag) substrate. In this
sense, proteolytic Abs (Ab-proteases) rep-resent Abs to provide proteolytic effects. Abs against myelin basic protein/MBP
with proteolytic activity exhibiting sequence-specific cleavage of MBP is of great value to monitor demyelination whilst in multiple
sclerosis (MS). The activity of Ab-proteases was first registered at the subclinical stages 1-2 years prior to the clinical illness. And
the activity of the Ab-proteases revealed significant correlation with scales of demy-elination and the disability of the patients
as well. So, the activity of Ab-proteases and its dynamics tested would confirm a high subclinical and predictive (translational)
value of the tools as applica-ble for personalized monitoring protocols. Of tremendous value are Ab-proteases di-rectly affecting
remodeling of tissues with multilevel architectonics (for instance, my-elin). By changing sequence specificity one may reach
reduction of a density of the negative proteolytic effects within the mye-lin sheath and thus minimizing scales of demyelination.
Ab-proteases can be pro-grammed and re-programmed to suit the needs of the body metabolism or could be designed for the
development of new cata-lysts with no natural counterparts. Further studies are needed to secure artificial or edited Ab-proteases
as translational tools of the newest generation to diagnose, to moni-tor, to control and to treat and rehabilitate MS patients
at clinical stages and to prevent the disorder at subclinical stages in persons-at-risks to secure the efficacy of regenerative
manipulations
.
ssuchkov57@gmail.comAntibody proteases as a novel biomarker and a
unique target to suit translational tools to be
applied for bioengineering and biopharma
Sergey Suchkov
1, 2, 3
, Noel Rose
4
, Aleks Gabibov
5
and Harry
Schroeder
6
1
I M Sechenov First Moscow State Medical University, Moscow, Russia
2
A I Evdokimov Moscow State Medical & Dental University, Moscow, Russia
3
EPMA (European Association for Prediction, Prevention and Personalized Medicine), Brus-sels,
European Union
4
Johns Hopkins Center for Autoimmune Disease Research, PAHO/WHO Collaborating Cen-ter for
Autoimmune Disorders, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
5
Institute for Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
6
Division of Immunology & Rheumatology-UAB, Birmingham, Alabama, USA
Am J Pharmacol Pharmacother 2018, Volume 5
DOI: 10.21767/2393-8862-C1-003